Figures & data
Table I. Comparison of characteristics of commonly available platelet function technology platforms (Some data are adapted from Michelson AD [Citation98]).
Michelson AD. Methods for the measurement of platelet function. Am J Cardiol 2009;103:20A–26A Rodgers RP, Levin J. Bleeding time: A guide to its diagnostic and clinical utility. Arch Pathol Lab Med 1990;114:1187–1188 Helgason CM, Bolin KM, Hoff JA, Winkler SR, Mangat A, Tortorice KL, Brace LD. Development of aspirin resistance in persons with previous ischemic stroke. Stroke 1994;25:2331–2336 Chamorro A, Escolar G, Revilla M, Obach V, Vila N, Reverter JC, Ordinas A. Ex vivo response to aspirin differs in stroke patients with single or recurrent events: A pilot study. J Neurol Sci 1999;171:110–114 Fong J, Cheng-Ching E, Hussain MS, Katzan I, Gupta R. Predictors of biochemical aspirin and clopidogrel resistance in patients with ischemic stroke. J Stroke Cerebrovasc Dis 2011;20:227–230 Sternberg Z, Ching M, Sawyer RN, Chichelli T, Li F, Janicke D, Radovic V, Mehta B, Farooq O, Munschauer FE. Clopidogrel responsiveness in stroke patients on a chronic aspirin regimen. J Stroke Cerebrovasc Dis 2013;22:725–732 Cattaneo M, Hayward CP, Moffat KA, Pugliano MT, Liu Y, Michelson AD. Results of a worldwide survey on the assessment of platelet function by light transmission aggregometry: A report from the platelet physiology subcommittee of the SSC of the ISTH. J Thromb Haemost 2009;7:1029 Cattaneo M. Light transmission aggregometry and ATP release for the diagnostic assessment of platelet function. Semin Thromb Hemost 2009;35:158–167 Ozaki Y, Satoh K, Yatomi Y, Yamamoto T, Shirasawa Y, Kume S. Detection of platelet aggregates with a particle counting method using light scattering. Anal Biochem 1994;218:284–294 Yamamoto J, Ishii I, Chikamori A, Sasaki Y, Nagamatsu Y, Morita S, Tsukahara M. Effect of long-term aerobic exercise on helium-neon-laser-induced thrombogenesis in rat mesenteric arterioles and platelet aggregation. Haemostasis 1993;23:129–134 Trentalange MJ, Walts LF. A comparison of thromboelastogram and template bleeding time in the evaluation of platelet function after aspirin ingestion. J Clin Anesth 1991;3:377–381 O'Brien JR, Salmon GP. Shear stress activation of platelet glycoprotein IIb/IIIa plus von Willebrand factor causes aggregation: Filter blockage and the long bleeding time in von Willebrand's disease. Blood 1987;70:1354–1361 Gorog P, Ahmed A. Haemostatometer: A new in vitro technique for assessing haemostatic activity of blood. Thromb Res 1984;34:341–357 Carr ME, Martin EJ, Kuhn JG, Spiess BD. Onset of force development as a marker of thrombin generation in whole blood: The thrombin generation time (TGT). J Thromb Haemost 2003;1:1977–1983 Coiffic A, Cazes E, Janvier G, Forestier F, Lanza F, Nurden A, Nurden P. Inhibition of platelet aggregation by abciximab but not by aspirin can be detected by a new point-of-care test, the hemostatus. Thromb Res 1999;95:83–91 Gorog DA, Kovacs IB. Thrombotic status analyser. Measurement of platelet-rich thrombus formation and lysis in native blood. Thromb Haemost 1995;73:514–520 Varon D, Lashevski I, Brenner B, Beyar R, Lanir N, Tamarin I, Savion N. Cone and plate(let) analyzer: Monitoring glycoprotein IIb/IIIa antagonists and von Willebrand disease replacement therapy by testing platelet deposition under flow conditions. Am Heart J 1998;135:S187–S193 Levy-Shraga Y, Maayan-Metzger A, Lubetsky A, Shenkman B, Kuint J, Martinowitz U, Kenet G. Platelet function of newborns as tested by cone and plate(let) analyzer correlates with gestational Age. Acta Haematol 2006;115:152–156 Carville DG, Schleckser PA, Guyer KE, Corsello M, Walsh MM. Whole blood platelet function assay on the ICHOR point-of-care hematology analyzer. J Extra Corpor Technol 1998;30:171–177 Kinsella JA, Tobin WO, Cox D, Coughlan T, Collins R, O'Neill D, Murphy RP, McCabe DJ. Prevalence of ex vivo high on-treatment platelet reactivity on antiplatelet therapy after transient ischemic attack or ischemic stroke on the PFA-100((R)) and VerifyNow((R)). J Stroke Cerebrovasc Dis 2013;22:e84–e92 Alberts MJ, Bergman DL, Molner E, Jovanovic BD, Ushiwata I, Teruya J. Antiplatelet effect of aspirin in patients with cerebrovascular disease. Stroke 2004;35:175–178 Agayeva N, Gungor L, Topcuoglu MA, Arsava EM. Pathophysiologic, rather than laboratory-defined resistance drives aspirin failure in ischemic stroke. J Stroke Cerebrovasc Dis 2015;24:745–750 Mannu GS, Macartney A, Lambert JR, Bettencourt-Silva JH, Lawn M, Lyall H, Metcalf AK, Potter JF, Wood J, Clark A, et al. The clinical utility of Multiplate analyser measurement in platelet function testing following stroke and transient ischaemic attack. Eur J Haematol 2015;94:138–144 Jastrzebska M, Chelstowski K, Wodecka A, Siennicka A, Clark J, Nowacki P. Factors influencing multiplate whole blood impedance platelet aggregometry measurements, during aspirin treatment in acute ischemic stroke: A pilot study. Blood Coagul Fibrinol 2013;24:830–838 von Lewinski F, Riggert J, Paulus W. Towards a rationale of platelet aggregation monitoring in stroke prophylaxis? J Stroke Cerebrovasc Dis 2009;18:111–115 Dharmasaroja PA, Sae-Lim S. Comparison of aspirin response measured by urinary 11-dehydrothromboxane B2 and VerifyNow aspirin assay in patients with ischemic stroke. J Stroke Cerebrovasc Dis 2014;23:953–957